In this section, we attempt to summarize the progress in targeting MDM2 to potentiate immunotherapies and discuss the potential of using STING agonists, p53-restoring agents, gene therapies, and immune-based therapies in targeting immune evasion in p53-mutant cancers (Figure 4). This evidence concerns the gene TP53 and cancer.